No description available.

No description available.

<p>Details on the CanWell program can be found at www.canwellprogram.ca</p> / <p>People with cancer face many challenges related to their disease and its associated treatments. This dissertation consists of two studies directly evaluating the effects of exercise on cancer survivors who participated in a community-based exercise program (CanWell program) and a measurement paper that evaluated a measure of symptom burden. The first study outlines the development and effectiveness of the CanWell program as measured by the 6-minute walk test, STEEP treadmill test, Functional Cancer Therapy Assessment – General, and the Edmonton Symptom Assessment System (ESAS). This study found that participants in the CanWell program have significantly improved physical abilities, improved quality-of-life, and lower levels of cancer disease burden. The second study was conducted to evaluate the long-term exercise compliance, facilitators and barriers to continuation of exercise. Outcome measures used were similar to those in the first study with a survey explored facilitators and barriers to exercise. The results of this study found that while CanWell graduates were able to maintain the functional levels (no change in 6-minute walk test), there were significant reductions in exercise aerobic abilities (time on treadmill). The main exercise barriers included fatigue, cost, and return to work. In the last study, the measurement properties of the ESAS were investigated using Rasch analysis leading to a revised scoring algorithm to meet unidimensionality and interval scaling. The ESAS scores from study #1 were re-analyzed using the new interval-level scoring scheme. This Rasch-based scoring resulted in different conclusions than the traditional ordinal scaling.</p> / Doctor of Philosophy (PhD)

<b><u>Introduction:</b></u> Some cancer survivors are known to have an elevated risk of morbidity and mortality from cardiovascular disease. An important cause of this elevated risk is recognised to be irradiation of normal tissues during radiotherapy received as part of cancer therapy. There are substantial difficulties in studying radiation-related cardiovascular disease (RRCD). The reasons for this include the complexities of measuring radiation normal tissue doses retrospectively and the prolonged latencies of many of the cardiovascular endpoints. A variety of complimentary research methodologies can help provide additional knowledge to guide the appropriate management of patients treated in the past and of new patients in the future. <b><u>Methods:</b></u> 1) A cohort study of mortality from circulatory disease in the nationwide British Childhood Cancer Survivor Study (BCCSS). 2) A case-control study of valvular heart disease (VHD) in Dutch Hodgkin lymphoma (HL) survivors, including retrospective radiation dosimetry to estimate the radiation dose to heart valves. 3) A dosimetric study of cardiovascular radiation doses in patients entered into the UK NCRI Lymphoma Study Group RAPID trial, including predictions of 15-year cardiac mortality using innovative methods. 4) A modelling study to predict mean whole heart dose (MWHD) from involved field radiotherapy (IFRT) for HL using anatomical measures. 5) A prospective study using cardiovascular magnetic resonance (CMR) imaging to characterise the heart in women receiving radiotherapy for breast cancer. <b><u>Results:</b></u> 1) The risks of all types of circulatory mortality are elevated in survivors of childhood cancer. The absolute excess risks continue to increase 40+ years following diagnosis. The risk of death from cardiomyopathy and heart failure increased substantially with the introduction of anthracycline chemotherapy. There is no evidence of a reduction in risk of circulatory mortality in more recent eras of diagnosis. 2) There is a strong relationship between estimated radiation dose to the affected heart valve and the risk of subsequent VHD (p<0.001). This effect was modelled to allow prediction of the risk of VHD. 3) A proportion of patients treated with IFRT received a substantial cardiac radiation dose (MWHD = 8.8 Gy, SD = 5.6) but, on average, the predicted 15-year cardiac mortality following treatment is low (absolute risk 0.2%, range 0.0 to 2.7%). 4) It is possible to estimate the mean whole heart dose from IFRT prior to detailed radiotherapy planning based on pre-treatment diagnostic imaging to an accuracy of 5-6% of the prescribed dose. 5) Although women received low cardiac doses (MWHD = 1.5 Gy, SD = 0.8) and have a low predicted risk of cardiac radiation-related morbidity and mortality, there is some evidence of subclinical effects on strain and strain rate imaging of the anterior portions of the left ventricle that receive the highest radiation dose. <b><u>Conclusions:</b></u> Using a variety of methods these studies have all succeeded in adding to knowledge about the nature, magnitude and timing of RRCD. This knowledge can be used to help the future management of cancer patients. In addition, each of the studies has natural and planned extensions and will continue to contribute further knowledge into the future.

Objective: The impact of childhood cancer on future quality of life (QoL) in survivors is unclear. Current studies focus on comparing outcomes to healthy peers and identifying related treatment and demographic variables, but a shift in our approach is necessary. This study is guided by the Wilson and Cleary Model (WMC) and seeks to identify longitudinal predictors of QoL in adolescent survivors of cancer that explain variance in QoL beyond the impact of treatment and demographic variables. Methods: The Childhood Cancer Survivor Study (CCSS) is a multi-institutional longitudinal study following a cohort of childhood cancer survivors. This study focuses on the CCSS cohort (N = 305) who completed the baseline survey in 1994 and the Teen survey in 2001. The baseline survey assessed parent-report of child’s psychological and physical symptoms, functional status, and health perceptions. The Teen survey utilized the Child Health and Illness Profile – Adolescent Edition (CHIP-AE), a self-report measure assessing QoL in six domains: achievement, resilience, satisfaction, discomfort, disorders, and risk. The primary hypothesis was that psychological and physical symptoms, functional status impairment, and health perceptions as rated by parents at baseline would predict variance in quality of life as rated by adolescents at follow-up after adjusting for demographic and treatment-related variables. Six separate hierarchical regressions were analyzed for each of the QoL domains. Results: The main hypothesis was supported. For each QoL outcome, a significant amount of variance was predicted: achievement, F (6, 259) = 8.90, p < .001, adjusted R2 = .152, resilience, F (12, 209) = 3.47, p < .001, adjusted R2 = .118, satisfaction, F (6, 265) = 8.73, p < .001, adjusted R2 = .146, discomfort, F (7, 273) = 6.75, p < .001, adjusted R2 = .126, disorders, F (9, 212) = 6.47, p < .0001, adjusted R2 = .182, and risk, F (7, 238) = 4.81, p < .001, adjusted R2 = .098. Furthermore, for all outcomes, psychological and physical symptoms, functional status impairment, and health perceptions predicted variance above and beyond the impact of demographic and treatment variables. These factors accounted for an additional 9.5% of the variance in the achievement domain, 6.2% for resilience, 10.8% for satisfaction, 6.5% for discomfort, 12.4% for disorders, and 6.1% for risk. Conclusions: Results suggest that psychological and physical symptoms, functional status and health perceptions should be assessed and targeted in interventions for childhood cancer survivors to promote future positive QoL. Future studies need to continue identifying factors related to positive long-term functioning in diverse samples of childhood cancer survivors.

Introdução: A duração da quimioterapia de primeira linha e seu impacto na sobrevida global dos pacientes com câncer colorretal metastático (CCRm) são controversos e, até o momento, estudos não conseguiram definir um claro padrão. Métodos: Revisão sistemática dos principais bancos de dados da literatura médica (MEDLINE, EMBASE e Cochrane Central Register of Controlled Trials), bem como trabalhos apresentados em congressos internacionais de oncologia (Sociedade Americana [ASCO] e Européia de Oncologia Clínica [ESMO]), em busca dos ensaios clínicos aleatorizados que compararam a sobrevida global (SG) dos pacientes com CCRm que receberam quimioterapia de primeira linha de forma contínua até progressão da doença versus parada completa de tratamento após um número fixo de ciclos de indução. O desfecho primário foi SG e os desfechos secundários incluíram desfechos de progressão do tipo tempo-para-evento, intervalo livre de quimioterapia, qualidade de vida e toxicidade. Uma meta-análise dos Hazard Ratios (HR) reportados para a SG foi realizada. Os estudos incluídos foram avaliados quanto às suas metodologias e análises de subgrupo foram realizadas quando heterogeneidades metodológicas foram encontradas. Análise de sensibilidade foi realizada quanto ao risco de viés, avaliado pela escala de Jadad, e quando teste de inconsistência de Higgins (I2) maior que 35% (heterogeneidade) foi encontrado. Resultados: A busca inicial resultou em 251 ensaios, dos quais 6 foram elegíveis e 5 forneceram dados suficientes para a meta-análise de SG (N = 3.061). A SG dos pacientes que receberam quimioterapia de forma contínua até progressão não foi estatisticamente diferente daqueles para quem foi oferecido parada completa de tratamento (HR = 0,93, IC95% = 0,84-1,03; I² = 12%; p = 0,15). Os resultados foram semelhantes quando analisados somente estudos classificados como de boa qualidade bem como nos subgrupos separados quanto ao momento de aleatorização (antes versus após terapia de indução) ou quanto ao uso ou não de anticorpo monoclonal. A mediana de intervalo livre de quimioterapia no grupo de parada completa foi de 3,9 meses (3,6 - 4,3 meses). A quimioterapia administrada até a progressão foi associada com mais efeitos adversos e pior qualidade de vida. Conclusão: Em comparação com a primeira linha de quimioterapia contínua administrada até progressão de doença, interromper completamente o tratamento não teve impacto negativo sobre a SG dos pacientes com CCRm. Identificação de biomarcadores preditivos poderia ajudar na seleção dos pacientes que provavelmente se beneficiariam de terapia direcionada ao câncer de forma contínua / Background: The impact of the duration of chemotherapy on the overall survival of patients with metastatic colorectal cancer (mCRC) is controversial and studies have failed to define a clear standard. Methods: We systematically searched medical literature databases (MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials), as well as oncology conferences proceedings (American Society of Clinical Oncology [ASCO] and European Society for Medical Oncology [ESMO] annual meetings) for randomized controlled trials (RCT) that compared the overall survival (OS) of mCRC patients who received first-line chemotherapy continuously until disease progression versus those who were offered complete treatment stop after a fixed number of cycles. The primary study endpoint was OS. The secondary endpoints were progression-free survival, chemotherapy-free interval, quality of life and rate of toxicities. A meta-analysis of reported Hazard Ratios for survival was performed. The studies included were evaluated for their methodologies and subgroup analyzes were performed when methodological heterogeneity was found. Sensitivity analysis was performed when relevant heterogeneity was found (defined as I²>35%). Results: We retrieved 251 trials, of which 6 were eligible and 5 were included in the pooled analysis of overall survival (N = 3,061). The overall survival between continuously delivered chemotherapy and complete stop was not statistically different (HR= 0.93, 95%IC = 0.84 to 1.03; p=0,15; I² = 12%). The results were similar when we analyzed separately only trials classified as high quality by Jadad scale and according to the following subgroups: trials that performing randomization before versus after induction therapy and according to the use of monoclonal antibody (yes or no). The median chemotherapy free interval in the complete-stop group was 3.9 months (3.6 - 4.3 months). Chemotherapy administered until progression was associated with more adverse effects and impaired quality of life. Conclusion: Compared with first-line continuous chemotherapy administered until disease progression, complete treatment stop did not have a detrimental impact on the overall survival of patients with mCRC. Identification of predictive biomarkers could help clinicians to select the patients who would benefit from continuous cancer-directed therapies

A hipertensão arterial pulmonar (HAP) é uma doença que acomete o território vascular pulmonar, gerando incapacidade funcional e falência cardíaca progressiva. Diversos marcadores de resposta têm sido desenvolvidos para a avaliação dos pacientes com HAP frente às novas modalidades terapêuticas desenvolvidas nos últimos anos, entre os quais o teste de caminhada de seis minutos é o mais utilizado. Embora seja simples, possui algumas limitações inerentes à técnica padrão, como por exemplo a necessidade de espaço físico adequado para sua realização. O objetivo deste trabalho foi elaborar e validar um protocolo de caminhada na esteira para a avaliação de pacientes com HAP. Os resultados mostraram correlação da distância caminhada em esteira com os dados hemodinâmicos, assim como com a classificação funcional e com a distância caminhada no solo. Além disso, a distância percorrida no teste em esteira apresentou correlação significativa com a sobrevida, confirmando portanto, sua correlação com a gravidade da doença. A inalação de óxido nítrico(NO) durante o teste de caminhada levou a variações compatíveis com as variações hemodinâmicas frente à mesma dose de NO, sugerindo que o protocolo em questão possa refletir intervenções terapêuticas. Conclui-se que o protocolo de caminhada na esteira é um marcador funcional e prognóstico para pacientes com HAP, constituindo-se em um instrumento útil na avaliação de rotina de pacientes com HAP. / Pulmonary arterial hypertension (PAH) is a disease affecting the pulmonary arterial territory leading to progressive functional impairment and heart failure. Many different surrogate markers have been studied to evaluate PAH patients under the different treatment strategies that have been developed during the last decade. Among these markers, the six-minute walk test is the most used one. Although simple, many limitations exist mainly related to the need of appropriate physical area to perform the test properly. The aim of this study was to develop and validate a treadmill six-minute walk test for PAH patients evaluation. The developed protocol well correlated with other markers of disease severity as invasive hemodynamic data, functional class and even the distance walk at the hallway six minute walk test. Furthermore, the treadmill walked distance was associated to survival thus strengthening its ability to reflect disease severity. Nitric oxide (NO) inhalation during the treadmill walk test led to a variation in the walked distance proportional to the hemodynamic changes induced by the same dose of inhaled NO, suggesting that the developed protocol may be able to reflect at least acute therapeutical interventions. We conclude that the treadmill six minute walk test is a useful prognostic and functional marker for the routine evaluation of PAH patients.

INTRODUÇÃO: O câncer do colo uterino é a terceira neoplasia maligna que mais afeta as mulheres brasileiras e, quando não detectada precocemente, apresenta prognóstico reservado. O câncer do colo uterino é consequência da infecção pelo Papilomavírus humano (HPV). Pouco é conhecido sobre a influência dos genótipos do HPV na apresentação clínica e o seu impacto na taxa de sobrevida no câncer do colo uterino. Os objetivos do estudo foram identificar os genótipos de HPV no tecido tumoral da população atendida no Instituto do Câncer do Estado de São Paulo e associar os genótipos de HPV aos fatores de risco conhecidos para o câncer do colo uterino. MÉTODOS: Foram incluídas mulheres com diagnóstico de câncer do colo uterino atendidas no Instituto do Câncer do Estado de São Paulo (ICESP) entre maio de 2008 e junho de 2012. A análise do material tumoral parafinado confirmou histologicamente o diagnóstico de câncer do colo uterino. O DNA tumoral foi extraído de três fragmentos de 10?m de espessura do bloco de parafina de carcinoma do colo uterino e submetido ao ensaio clínico Onclarity (sistema automatizado da BD Viper LT) para detecção e genotipagem do HPV. Idade ao diagnóstico, estadiamento clínico, tipo histológico e tempo de sobrevida foram obtidos a partir de registros do prontuário até dezembro de 2015. RESULTADOS: Foram analisadas 414 pacientes. As frequências dos genótipos estudados foram HPV16 (54%) HPV18(9%), HPV33-­58 (6%), HPV45 (5%), HPV31 (3%), HPV39-­68-­ 35 (3%), HPV59-­56-­66(3%), HPV52 (2%) e HPVnegativo (14%). A idade da população estudada variou de 17 a 87 anos, com média etária de 50,8 (DP=13,8 anos). Os tipos histológicos foram carcinoma de células escamosas (75%), adenocarcinoma (21%) e outros tipos histológicos (4%). Conforme o estadiamento clínico adotado pela FIGO (2009), 35% foi classificado como 1A1, 1A2 e 1B1, 17% como 1B2 e 2A e 48% como 2B a 4B. O genótipo do HPV apresentou distribuição diferente quanto à idade ao diagnóstico, tipo histológico e estadiamento. A mediana do tempo de sobrevida global desta coorte de pacientes com câncer do colo uterino foi de 37 meses [12-­53 meses]. A sobrevida global acumulada em 5 anos após o diagnóstico de câncer do colo uterino foi de 55%. Ocorreram 119 (38%) óbitos no período e 133 (42%) recidivas subdivididas em três grupos: local (12%), regional (30%) e à distância (58%). Curvas de sobrevida de Kaplan-­Meier e estatística de Log-­rank demonstraram que os genótipos de HPV 16 e 18 (59%) não se relacionaram a um pior prognóstico em comparação com outros genótipos de HPV (41%) (P=0,17). Idade ao diagnóstico, estadiamento clínico, tipo histológico, invasão vascular, metástase linfonodal, tamanho do tumor e os genótipos HPV16, HPV18 e HPVoutros foram analisados individualmente em um modelo de regressão de Cox. O genótipo do HPV se associou a pior taxa de sobrevida global apenas quando detectado mais de um HPV no material tumoral analisado. CONCLUSÃO: Apesar das diferentes distribuições dos os genótipos do HPV quanto à idade ao diagnóstico, tipo histológico e estadiamento, o genótipo do HPV não se mostrou como fator prognóstico independente no câncer do colo uterino / INTRODUCTION: Uterine cervical cancer is the third most common malignant neoplasm affecting Brazilian women. Prognosis is poor when diagnosis is delayed. Cervical cancer is a consequence of human papillomavirus (HPV) infection. Little is known about the influence of HPV genotypes in Brazil and its impact on cancer survival rate The purpose of the present study were to identify HPV genotypes of tumoral tissue from the affected population and to examine the association between HPV genotype and traditional cervical cancer risk factors. METHODS: Women diagnosed with cervical cancer at the Cancer Institute of the State of São Paulo (ICESP) between May 2008 and June 2012 were included in the study. Tumor specimens were reviewed to confirm the diagnosis of cervical cancer. Tumor DNA was extracted from three 10?m-­thick paraffin block fragments of each subject. HPV genotype was detected using the Onclarity system (BD Viper LT automated system). Age at diagnosis, clinical staging, histological type and survival time were obtained from the hospital electronic data records until December 2015. RESULTS: 414 patients were analyzed. The HPV genotypes studied were HPV16 (54%) HPV18 (9%), HPV33-­58 (6%), HPV45 (5%), HPV31 (3%), HPV39-­68-­35 (3%), HPV59-­56-­ 66(3%), HPV52 (2%) and HPVnegative (14%). The age of the study population ranged from 17 to 87 years, mean age= 50.8 (SD=13.8 years). Histological types were classified as squamous cell carcinoma (75%), adenocarcinoma (21%) and other histological types (4%). According to the 2009 FIGO clinical staging, 35% were classified as 1A1, 1A2 and 1B1, 1B2 and 17% as 2A and 48% as 2B the 4B. HPV genotypes showed different distributions regarding age, histologic tumor types and clinical staging. The median overall survival time was 37 months [12-­53 months]. The cumulative overall survival at 5 years after diagnosis of cervical cancer was 55%. There were 119 (38%) deaths during the study period and 133 (42%) recurrences subdivided into three groups: local (12%), regional (30%) and distant (58%). Kaplan-­Meier survival curves and Log-­rank statistics showed that HPV 16/18 (59%) did not influence prognosis compared to other HPV subtypes (41%) (P=0.17). Age at diagnosis, clinical stage, histological type, vascular invasion, lymph node metastasis, tumor size and HPV16 genotypes, HPV18 and HPVothers were individually analyzed in a Cox regression model. HPV genotype was associated with poorer overall survival rate only when multiple HPV infection was detected in the tumoral specimen. CONCLUSION: Although HPV genotype showed different distribution regarding age at diagnosis, histological type and clinical staging, HPV genotype was not an independent prognostic factor of cervical cancer in the study population

O câncer de pênis é uma doença de baixa incidência e sua manifestação está associada a fatores intrínsecos e extrínsecos, e sua principal forma de tratamento é a penectomia. Devido à doença ocorrer no órgão genital masculino busquei conhecer como os homens adoecidos lidam com suas masculinidades na situação do adoecimento. Dessa forma, propus a tese de que a cultura influencia na forma como os homens sobreviventes do câncer de pênis lidam com suas masculinidades. Elaborei o objetivo de interpretar os significados atribuídos à experiência com o câncer de pênis e seus tratamentos pelos homens adoecidos. O referencial teórico adotado foi o da antropologia médica e das masculinidades, pois ambas consideram a cultura como um elemento importante no mundo social. Para conhecer a cultura do outro é necessário vivenciá-la de perto, por este motivo optei por desenvolver a etnografia narrativa. Esse método propõe ao pesquisador o uso de técnicas como a observação participante, múltiplas entrevistas, uso do diário de campo, análise temática e a apresentação dos resultados na estrutura de narrativas que contenham a estória das vivências dos participantes. Ressalto que a narrativa tem como principal objetivo mostrar as transformações vividas pelos depoentes, considerando os aspectos comuns e divergentes dos entrevistados. Foram selecionados 18 homens com o diagnóstico de câncer de pênis no ambulatório de uro- oncologia de um hospital do interior paulista. As características sociais e clínicas dos entrevistados são semelhantes aos dados nacionais e internacionais em relação à baixa incidência da doença, faixa etária e os tratamentos empregados. Diante do processo de análise foi possível construir oito sínteses temáticas: O câncer de pênis e seu itinerário; O corpo após a doença e seus tratamentos; O câncer e suas repercussões sociais: o trabalho, o lazer e as relações sociais; Por trás do visível: a confidencialidade da doença; A sexualidade pós- tratamento; Um homem inteiro ou meio homem: a ressignificação das masculinidades; Recursos de apoio social; O hoje e as expectativas para o futuro. Por meio das sínteses narrativas é possível conhecer os sentidos que os homens empregaram ao adoecimento e como a doença afetou sua masculinidade. Estes achados permitiram alcançar o significado de ser homem sobrevivente do câncer de pênis e seus tratamentos, que pode ser compreendido pela expressão \"ser meio homem\". Desde o início do diagnóstico até a vida no pós- tratamento, os homens negociam suas masculinidades com o mundo social, e percebem que algumas características adquiridas durante o adoecimento os tornam diferente dos demais homens, tais como se assumir doente, a extirpação total ou parcial do pênis, redução da força física, impossibilidade de trabalhar e alterações na prática sexual. Comprovo, então, que a cultura tem influência na forma que os homens lidam com suas masculinidades, uma vez que os adoecidos constantemente revisitam seus padrões culturais de masculinidade para obedecê- lo ou ressignificá-lo. Os enfermeiros podem utilizar os achados deste estudo para refletir sua prática de cuidado aos homens com câncer e para desenvolverem outras pesquisas que o complementem / Penile cancer is a disease of low incidence, and its manifestation is associated with intrinsic and extrinsic factors, and its main form of treatment is the penectomy. Due to the fact that the disease occurs in the male genital organ, I sought to know how the ill men deal with their masculinities in the disease situation. Thus, I proposed the thesis that culture influences in the way as the penile cancer survivors deal with their masculinities. The aim of this study is to interpret the meanings attributed to the experience with penile cancer and its treatments by the ill men. The theoretical framework adopted was medical anthropology and masculinities, since both considered culture as an important element in the social world. In order to understand the culture of the other people is necessary to experience it closely, for this reason I chose to develop the narrative ethnography. This method proposes to the researcher the use of techniques such as participant observation, mult iple interviews, the use of field diary, thematic analysis and the presentation of results in the structure of narratives that contain the story of participants\' experiences. I emphasize that the narrative has as main objective to show the transformations lived by the deponents, considering the common and divergent aspects of the interviewees. We selected 18 men with the diagnosis of penile cancer in the uro-oncology clinic of a hospital in the interior of São Paulo. The social and clinical characteristics of the interviewees are similar to the national and international data regarding the low incidence of the disease, age group and the treatments used. From the process of analysis it was possible to construct eight thematic syntheses: Penile cancer and its itinerary; The body after disease and its treatments; Cancer and its social repercussions: work, leisure and social relations; Behind the visible: the confidentiality of the disease; The sexuality post-treatment; The whole man or half man: resignification of masculinities; Social support resources; The today and expectations for the future. Through narrative syntheses it was possible to comprehend the meaning attributed by the patients, what they assigned to illness and how that disease affected their masculinity. These findings allowed us to achieve the meaning of being a man penile cancer survivor and its treatments, which can be understood by the expression \"being half man\". From the onset of diagnosis up to life post-treatment, men negotiate their masculinities with the social world, and realize that some characteristics acquired during illness make them different from other men, such as, to assume themselves as sickness, the fact that they have total or partial penile extirpation, reduction of physical strength, impossibility of working and changes in sexual practice. I then show that culture influences the way men deal with their masculinities, since the ill men are constantly revisiting their cultural patterns of masculinity to obey or re-signify it. Nurses can use the findings of this study to reflect their practice of caring for men with cancer and to develop further researches that complements this one

Introdução. O Fluxo Gerenciado FGC20 é um protocolo institucional que define as etapas do tratamento neoadjuvante para adenocarcinoma de reto, com quimioterapia e radioterapia concomitantes e posterior cirurgia. Sua implantação no Instituto do Câncer do Estado de São Paulo (ICESP), a partir de março de 2011, envolveu as áreas assistenciais médicas, multiprofissionais e administrativas, com o estabelecimento da sequência das etapas e intervalos desejáveis. Objetivos. Avaliar a implantação do modelo de gerenciamento do protocolo clínico institucional para o tratamento neoadjuvante do adenocarcinoma de reto, nomeado Fluxo Gerenciado FGC20, adotado no ICESP. Pacientes e métodos. Foi construído um modelo lógico operacional para descrever o processo de implantação do fluxo gerenciado FGC20. Indicadores de monitoramento foram definidos a partir do modelo lógico e comparados com o período prévio à implantação. Dois grupos foram comparados: grupo controle, de pacientes cuja entrada ocorreu entre 06/05/2008 a 11/05/2011(prévio à implantação, nomeado grupo PreFluxo); e grupo experimental, de pacientes com início de atendimento entre 12/05/2011 a 31/12/2013 (posterior à implantação, nomeado grupo FGC20). Foram incluídos pacientes consecutivos, com diagnóstico de câncer de reto, tratados com quimioterapia e radioterapia concomitantes e posterior realização de cirurgia, e excluídos pacientes metastáticos ao diagnóstico inicial, pacientes com tratamento prévio ao início do tratamento no serviço e pacientes que não realizaram o tratamento neoadjuvante. Foram observados os intervalos de tempo entre as etapas do tratamento e recursos utilizados, dentre consultas, exames, internações, quimioterapia, radioterapia e cirurgia. O estudo de descrição de custos foi apresentado em Reais de 2015 na perspectiva do serviço. Resultados. De um total de 624 pacientes, foram analisados 330 pacientes: 112 do grupo PréFluxo e 218 do grupo FGC20. Em relação aos indicadores de monitoramento da implantação, 66% dos pacientes do grupo FGC20 realizaram a 1ª consulta no intervalo < 15 dias, 75% dos pacientes ficaram dentro da meta esperada de 14 semanas para o intervalo entre o final da neoadjuvância e a cirurgia (mediana de 13,2 semanas grupo FGC20 e 20 semanas grupo PréFluxo) e 73% dos pacientes completaram todas as etapas do fluxo gerenciado no intervalo <189 dias (mediana de 176,4 dias grupo FGC20 e 261,5 dias grupo PréFluxo). No grupo PréFluxo, houve maior número de consultas com oncologistas clínicos, tomografias computadorizadas, ressonâncias magnéticas e sessões de radioterapia (p < 0,001), bem como maior média de eventos de passagens no Setor de Emergência e na Unidade de Terapia Intensiva, em relação ao grupo FGC20 (p<0,001) e a média de custo por paciente tratado no grupo PréFluxo foi de R$ 40.935,68 e mediana de R$ 37.948,05. No grupo Fluxo Gerenciado, a média de custo por paciente tratado foi de R$ 40.368,18 e a mediana de R$ 35.341,32 respectivamente. A média de sobrevida global foi de 5,99 (5,59-6,40) e de 7,01 (6,47-7,54) anos, para os grupos PreFluxo e FGC20, respectivamente (p=0,83). Conclusões. A implantação do fluxo gerenciado promoveu reduções em todos os intervalos de tempo entre as etapas do tratamento. Não houve diferenças estatisticamente significantes na sobrevida global e no custo por paciente tratado entre os grupos. Custos de diárias e consultas foram os segmentos mais representativos no custo total do tratamento do paciente com câncer de reto / Background. The FGC20 is an integrated care pathway started in May 2011 at Instituto do Cancer do Estado de Sao Paulo (ICESP) for neoadjuvant treatment of adenocarcinoma of rectum. The implementation involved a multidisciplinary team to standardize patient care and to define steps, interventions and goals. Objectives. To evaluate the implementation of a clinical care pathway of rectal cancer in a Brazilian tertiary academic oncology hospital. Patients and Methods: An operational logical model of the integrated care pathway was developed to describe the pathway implementation. Two cohorts of diagnosed rectal cancer patients were compared: a control cohort from May 06th, 2008 through May 11th, 2011 (before the implementation, named group Pre FGC20), and a cohort from May 12th, 2011 through December 31th, 2013 (after implementation, named group FGC20). We included consecutive patients treated with concomitant chemoradiotherapy (nCRT) followed by surgery. Patients with prior treatment or who have not performed the nCRT treatment or with metastatic disease at diagnosis were excluded. Time intervals between treatment steps and resources used, including consultations, exams, hospitalizations, chemotherapy, radiotherapy and surgery were assessed. Cost description study from the hospital perspective is presented in 2015 Reais. Results. From a total of 624 patients, 330 were included: 112 PreFGC20 and 218 FGC20. Implementation indicators of the group FGC20 were identified based on the logic model: 66% had the first consultation < 15 days, 75% < 14 weeks interval between the neoadjuvant treatment and surgery (Group PreFGC20: 20 weeks, median; group FGC20: 13.2 weeks, median) and 73% < 189 days to complete all treatment steps (Group PreFGC20: 261.5 days, median; group FGC20: 176.4 days, median). We found higher utilization of consultations with clinical oncologists, CT, MRIs and radiotherapy sessions in the Group PreFGC20 compared with the FGC20 Group (p < 0.001), and also more utilization of emergency room and intensive care unit in Group PreFGC20 (p < 0.001). Median cost per treated patient in Group PreFGC20 was R$ 37.948,05 and mean cost was R$ 40.935,68. Median cost per treated patient in Group FGC20 was R$ 35.341,32 and mean cost was R$ 40.368,18. The mean overall survival in the Pre-MFC20 group and MFC20 group were 5.99 (5.59-6.40) and 7.01 (6.47-7.54) years, respectively (p=0.83) Conclusions. The implementation of the ICP promoted reductions in all time intervals between treatment steps. There were no statistically significant difference in overall survival and cost per patient treated between the groups. Daily costs and consultations were the most representative segments in total cost of the rectal cancer patient treatment